Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lycopene Chemoprevention for Uremia-Associated Urothelial Carcinoma
NCT00172367Phase 2Withdrawn
- Sponsor
- National Taiwan University Hospital
- Start
- Jan 2006
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lycopene in urothelial carcinoma (UC), sponsored by National Taiwan University Hospital. Primary endpoint: Changes of intermediate biomarker status at 12 weeks. Planned start Jan 2006; status: withdrawn.
02
Drugs
lycopene
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00172367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00172367.